CP and lung cancer: The ability of sera from advanced (n = 30) and resectable (n = 39) PDAC patients (Table 1) to react against human recombinant EZR was compared to that of sera from HS (n = 45), non-PDAC tumor (n = 28; 8 breast, 8 colon, 12 lung cancer), CP (n = 37) and AD patients (n = 12).